The overall goal of this proposal is to determine if molecular markers found in pretreatment biopsy specimens can predict pathologic complete response (pathCR) in patients with esophageal cancer (EC) undergoing preoperative chemoradiation (CTRT). PathCR is defined as no residual carcinoma in a resected specimen. Patients with EC have a 5-year survival rate of <20%. Localized carcinoma (stage II or III) is frequently treated with preoperative CTRT, but this empirical approach results in heterogeneous and often unpredictable outcomes. Approximately 25% of patients achieve a pathCR and tend to survive longer than do the 75% who achieve
This proposal is an early attempt to individualize therapy based on molecular biology for patients with esophageal cancer. Our goal is to pave the way for a strategy in the future that will allow administration of effective therapy, improve safety, and preserve the esophagus in some patients. ? ? ?
Showing the most recent 10 out of 31 publications